Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Expert Opinion on Drug Safety|August 9, 2003
Safety profile of the triptansStewart J Tepper, David MillsonPharmacoepidemiology and Drug Safety|March 5, 2004
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trialsDarren M Ashcroft, David MillsonRheumatology (Oxford, England)|November 30, 2020
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X studyYoshiya Tanaka, David Millson, Shigeru Iwata, et al.Pharmacoeconomics|March 13, 2002
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) StudyMark Sculpher, David Millson, David Meddis, et al.Journal of Epidemiology and Community Health|November 18, 2004
Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and WalesMartin Frisher, Juliet Collins, David Millson, et al.Journal of Epidemiology and Community Health|September 17, 2005
Substance misuse and psychiatric illness: prospective observational study using the general practice research databaseMartin Frisher, Ilana Crome, John Macleod, et al.Clinical Therapeutics|November 1, 2015
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical StudiesPaul Martin, Stuart Oliver, Michael Gillen, et al.Clinical Therapeutics|October 31, 2015
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.Clinical Pharmacology in Drug Development|May 11, 2016
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.Journal of Public Health (Oxford, England)|December 16, 2004
What has happened to antimicrobial usage in primary care in the United Kingdom since the SMAC report? - description of trends in antimicrobial usage using the General Practice Research DatabaseGillian E Smith, Sue Smith, Heath Heatlie, et al.Pageof 2